Company: PRME
Filing Date: 2025-05-19
Form Type: DEFA14A
Source: 0001193125-25-122158
Chunk: 2

Company: Prime Medicine, Inc.
Filing Date: 2025-05-19
Form: DEFA14A
Chunk 2
---
 to which Dr. Gottesdiener is entitled to receive severance benefits in accordance with the terms of his Amended and Restated Employment Agreement, dated July 7, 2022, as amended by the Amendment
No. 1 to Employment Agreement, dated July 6, 2023, with the Company (as amended, the “Gottesdiener Employment Agreement”).

On the
effective date of the Resignation, as contemplated by the Gottesdiener Employment Agreement, the Company will retain certain non-exclusive, limited consulting and advisory services of Dr. Gottesdiener for
a period of up to one year from the effective date of the Resignation (the “Advisory Period”). During the Advisory Period, all of Dr. Gottesdiener’s outstanding equity awards will continue to vest in accordance with their terms.
Additionally, on the effective date of the Resignation, the Company entered into a Consulting Agreement with KMG Strategic Consulting, LLC, a limited liability company managed by Dr. Gottesdiener, to provide for Dr. Gottesdiener’s
continued consulting services to the Company, with the option, if mutually agreed, to extend such services beyond the one-year anniversary of the effective date of the Resignation (the “Consulting
Agreement”).

The foregoing summaries of the Separation Agreement and Consulting Agreement do not purport to be complete and are qualified in their
entirety by references to the full texts of the Separation Agreement and Consulting Agreement, copies of which the Company intends to file as exhibits to its Quarterly Report on Form 10-Q for the quarter
ending June 30, 2025.

Appointment of Chief Executive Officer and Principal Executive Officer

In connection with the Resignation, on May 16, 2025, the Board appointed Allan Reine, M.D., the Company’s Chief Financial Officer and principal
financial officer, as Chief Executive Officer and principal executive officer of the Company, in addition to continuing in his current role as principal financial officer of the Company, in each case effective as of May 19, 2025. The Board also
appointed Dr. Reine to serve as a member of the Board as a Class II director to hold office until the Company’s annual meeting of stockholders to be held in 2027, until his successor is elected and qualified, or until his earlier
death, resignation or removal, or until otherwise determined by the Board, effective as of May 19, 2025